-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For medical professionals to read and refer to clinical information only, 1s voclosporin (voclosporin) is a new generation of calcineurin inhibitor (CNi), which can be used to prevent rejection after organ transplantation and treat autoimmunity Disease
.
Fucyclosporine is a derivative of cyclosporine, which has stronger enzyme inhibitory activity and lower nephrotoxicity than cyclosporine [1]
.
Recently, Lancet, a top medical journal, published the results of a phase 3 clinical trial of Fucyclosporine for the treatment of patients with lupus nephritis, which evaluated the effectiveness and safety of Fucyclosporine in the treatment of lupus nephritis.
Get up and take a look at today's newsletter! Want to track the subject areas you care about in real time? Want to see more previous issues of "Top Journal Essentials"? Hurry up to the "Clinical Assistant in the Medical Field" service account to have a look! Step 1: Follow the official account of "Clinical Assistant in Medical Field" Step 2: Find "Subscription Settings" in the menu bar below to subscribe to the subject (subscribe to the subject’s daily push, read the new top issue every day) Step 3: Find it in the menu bar below "Top Journal Essentials" to view the contents of previous issues (multiple keyword selection, key research not to be missed), read the cutting-edge literature every day, so let's use such a useful tool! References [1] Li Pengmei, Zhang Ming, Zhang Xianglin.
A new calcineurin inhibitor, voltcycline[J].
Chinese Journal of New Drugs,2013,22(24):2841-2846.
Source of this article: Clinical Assistant in the Medical Field Responsible editor: Xiaodangdang Sun Ying's medical community strives to be accurate and reliable when its published content is reviewed and approved, but does not make any promises or promises regarding the timeliness of published content, and the accuracy and completeness of the cited information (if any).
It guarantees, and does not assume any responsibility due to the outdated content and the possible inaccuracy or incompleteness of the cited information
.
Relevant parties are requested to check separately when adopting or using this as a basis for decision-making
.
.
Fucyclosporine is a derivative of cyclosporine, which has stronger enzyme inhibitory activity and lower nephrotoxicity than cyclosporine [1]
.
Recently, Lancet, a top medical journal, published the results of a phase 3 clinical trial of Fucyclosporine for the treatment of patients with lupus nephritis, which evaluated the effectiveness and safety of Fucyclosporine in the treatment of lupus nephritis.
Get up and take a look at today's newsletter! Want to track the subject areas you care about in real time? Want to see more previous issues of "Top Journal Essentials"? Hurry up to the "Clinical Assistant in the Medical Field" service account to have a look! Step 1: Follow the official account of "Clinical Assistant in Medical Field" Step 2: Find "Subscription Settings" in the menu bar below to subscribe to the subject (subscribe to the subject’s daily push, read the new top issue every day) Step 3: Find it in the menu bar below "Top Journal Essentials" to view the contents of previous issues (multiple keyword selection, key research not to be missed), read the cutting-edge literature every day, so let's use such a useful tool! References [1] Li Pengmei, Zhang Ming, Zhang Xianglin.
A new calcineurin inhibitor, voltcycline[J].
Chinese Journal of New Drugs,2013,22(24):2841-2846.
Source of this article: Clinical Assistant in the Medical Field Responsible editor: Xiaodangdang Sun Ying's medical community strives to be accurate and reliable when its published content is reviewed and approved, but does not make any promises or promises regarding the timeliness of published content, and the accuracy and completeness of the cited information (if any).
It guarantees, and does not assume any responsibility due to the outdated content and the possible inaccuracy or incompleteness of the cited information
.
Relevant parties are requested to check separately when adopting or using this as a basis for decision-making
.
